• Rachael L Parke, Shay P McGuinness, Alana Cavadino, Keri-Anne Cowdrey, Samantha Bates, Shailesh Bihari, Amanda Corley, Eileen Gilder, Carol Hodgson, Edward Litton, Colin McArthur, Alistair Nichol, Jane Parker, Anne Turner, Steve Webb, Frank Mp Van Haren, and SAGE-ANZ Study Investigators and the Australia and New Zealand Intensive Care Society Clinical Trials Group.
• Cardiothoracic and Vascular Intensive Care Unit, Te Toka Tumai Auckland, Auckland, New Zealand.
• Crit Care Resusc. 2024 Sep 1; 26 (3): 161168161-168.

ObjectiveAcute respiratory distress syndrome (ARDS) is associated with significant mortality, morbidity, and cost. We aimed to describe characteristics and management of adult patients admitted to intensive care units (ICUs) in Australia and New Zealand with moderate-severe ARDS, to better understand contemporary practice.DesignBi-national, prospective, observational, multi-centre study.Setting19 ICUs in Australia and New Zealand.ParticipantsMechanically ventilated patients with moderate-severe ARDS.Main Outcome MeasuresBaseline demographic characteristics, ventilation characteristics, use of adjunctive support therapy and all-cause mortality to day 28. Data were summarised using descriptive statistics.Results200 participants were enrolled, mean (±SD) age 55.5 (±15.9) years, 40% (n = 80) female. Around half (51.5%) had no baseline comorbidities and 45 (31%) tested positive for COVID-19. On day 1, mean SOFA score was 9 ± 3; median (IQR) PaO2/FiO2 ratio 119 (89, 142), median (IQR) FiO2 70% (50%, 99%) and mean (±SD) positive end expiratory pressure (PEEP) 11 (±3) cmH2O. On day one, 10.5% (n = 21) received lung protective ventilation (LPV) (tidal volume ≤6.5 mL/kg predicted body weight and plateau pressure or peak pressure ≤30 cm H2O). Adjunctive therapies were received by 86% (n = 172) of patients at some stage from enrolment to day 28. Systemic steroids were most used (n = 127) followed by neuromuscular blockers (n = 122) and prone positioning (n = 27). Median ventilator-free days (IQR) to day 28 was 5 (0, 20). In-hospital mortality, censored at day 28, was 30.5% (n = 61).ConclusionsIn Australia and New Zealand, compliance with evidence-based practices including LPV and prone positioning was low in this cohort. Therapies with proven benefit in the treatment of patients with moderate-severe ARDS, such as lung protective ventilation and prone positioning, were not routinely employed.© 2024 The Authors.

4 keywords...

hide…